Sun Pharma Wins FDA Approval for Generic Sinemet CR Tablets
Posted on: Thursday, 6 November 2008, 09:00 CST
Sun Pharmaceutical Industries, a specialty pharmaceutical company, has received the FDA approval for the company's abbreviated new drug application for generic Sinemet CR, an extended release version of carbidopa with levodopa.
Carbidopa with levodopa extended release is indicated for the treatment of Parkinson's disease and syndrome.
These generic extended release versions of carbidopa with levodopa are bio-equivalent to Sinemet CR marketed by Bristol-Myers and Squibb Company and will be available as tablets in two strengths: 25mg carbidopa with 100mg levodopa and 50mg carbidopa with 200mg levodopa. The company expects to reach the market shortly with these products.
Source: Datamonitor
Related Articles
- Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan
- Digi Releases Extended-Range RF Module Designed for ZigBee Mesh Networking
- IMPAX Receives FDA Non-Approvable Letter for Vadova(R); Company Considering Options
- IMPAX Files Amendment to Vadova(TM) NDA
- Informative Graphics' Free DWG Viewer 5.4 Release Extends Support to AutoCAD 2007
- Sandwork Spice Explorer and WaveView Analyzer 2006.1 Release Extends Support to Simulation Analysis, Hardware Measurement, and System-Level Modeling
- IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
- Twice As Many Parkinson's Disease Patients Prefer Orally Dissolving Form of Carbidopa-Levodopa to Conventional Tablets
- Egenera Inc. Releases BladeFrame 4.0; Fourth-Generation Virtualization Platform Further Simplifies Customer Environments
- ADIC AMASS For UNIX Software Extends Infinite File Life to New Media; Expands Supported Storage Devices
 |
 |
User Comments (0)
RSS Feeds